Opinions
Jim Cramer - Mad Money
Bausch & Lomb Inc.
BOL-N
BUY
Feb 21, 2024
N/A
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Has gone through a transition. Was suffering a few years ago when it lost its momentum, R&D lagged. Can see some growth opportunity in their new lens. New president has shaken down the company, cut costs and re-invigorated their R&D. Has exceeded expectations for 13 quarters.
biotechnology
pharmaceutical
Advertising
It just reported clean top and bottom line beats with good results across all three divisions. Management raised its full-year sales forecast.